Actuate Therapeutics, Common Stock Fundamentals
| ACTU Stock | 6.56 0.05 0.76% |
Actuate Therapeutics,'s fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Actuate Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Actuate Therapeutics, Common Company Shares Owned By Institutions Analysis
Actuate Therapeutics,'s Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Actuate Therapeutics, Shares Owned By Institutions | 49.72 % |
Most of Actuate Therapeutics,'s fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Actuate Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Actuate Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Actuate Therapeutics, is extremely important. It helps to project a fair market value of Actuate Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Actuate Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actuate Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actuate Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 49.72% of Actuate Therapeutics, Common are shares owned by institutions. This is 11.38% higher than that of the Biotechnology sector and 4.67% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 26.8% lower than that of the firm.
Actuate Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Actuate Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Actuate Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Actuate Therapeutics, competition to find correlations between indicators driving Actuate Therapeutics,'s intrinsic value. More Info.Actuate Therapeutics, Common is rated below average in return on asset category among its peers. It is rated third in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Actuate Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Actuate Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actuate Therapeutics,'s direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actuate Therapeutics, could also be used in its relative valuation, which is a method of valuing Actuate Therapeutics, by comparing valuation metrics of similar companies.Actuate Therapeutics, is currently under evaluation in shares owned by institutions category among its peers.
Actuate Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Actuate Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Actuate Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Actuate Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 160.19 M | ||||
| Shares Outstanding | 23.24 M | ||||
| Shares Owned By Insiders | 16.14 % | ||||
| Shares Owned By Institutions | 49.72 % | ||||
| Number Of Shares Shorted | 483.57 K | ||||
| Price To Book | 14.05 X | ||||
| EBITDA | (25.16 M) | ||||
| Net Income | (27.29 M) | ||||
| Total Debt | 404.99 K | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (21.84 M) | ||||
| Short Ratio | 7.32 X | ||||
| Earnings Per Share | (3.11) X | ||||
| Target Price | 26.75 | ||||
| Number Of Employees | 10 | ||||
| Market Capitalization | 136.67 M | ||||
| Total Asset | 9.32 M | ||||
| Retained Earnings | (132.38 M) | ||||
| Working Capital | 405.4 K | ||||
| Net Asset | 9.32 M |
About Actuate Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actuate Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actuate Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actuate Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics,'s price analysis, check to measure Actuate Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics, is operating at the current time. Most of Actuate Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics,'s price. Additionally, you may evaluate how the addition of Actuate Therapeutics, to your portfolios can decrease your overall portfolio volatility.